Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caryn Tong

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Discovery Medicine|August 14, 2010
SensiparCaryn Tong
Discovery Medicine|August 14, 2010
AlimtaCaryn Tong
Oncoimmunology|February 6, 2018
CCL3 augments tumor rejection and enhances CD8<sup>+</sup> T cell infiltration through NK and CD103<sup>+</sup> dendritic cell recruitment via IFNγFrederick Allen, Iuliana D Bobanga, Peter Rauhe, et al.
Frontiers in Immunology|November 8, 2017
CCL3 Enhances Antitumor Immune Priming in the Lymph Node <i>via</i> IFNγ with Dependency on Natural Killer CellsFrederick Allen, Peter Rauhe, David Askew, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Discovery Medicine|August 14, 2010
SensiparCaryn Tong
Discovery Medicine|August 14, 2010
AlimtaCaryn Tong
Oncoimmunology|February 6, 2018
CCL3 augments tumor rejection and enhances CD8<sup>+</sup> T cell infiltration through NK and CD103<sup>+</sup> dendritic cell recruitment via IFNγFrederick Allen, Iuliana D Bobanga, Peter Rauhe, et al.
Frontiers in Immunology|November 8, 2017
CCL3 Enhances Antitumor Immune Priming in the Lymph Node <i>via</i> IFNγ with Dependency on Natural Killer CellsFrederick Allen, Peter Rauhe, David Askew, et al.
Pageof 1